Thermo Fisher Scientific Inc.
- Open
- 508.32
- Day high
- 508.38
- Day low
- 495.10
- Prev close
- 506.42
- Volume
- 2.3M
- Mkt cap
- $186.5B
- P/E (TTM)
- 27.5
- EPS (TTM)
- $18.21
- P/B
- 3.6
- P/S
- 4.1
- Yield
- 0.19%
- Per share
- $0.94
- ▼Insiders net selling -$185K over the last 3 months (0 open-market buys, 1 sale)
- 🏛Institutions mixed (13F)
Thermo Fisher Scientific Inc. (TMO) is a Healthcare company listed on NYSE. The stock is up 25% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 1 sale (SEC Form 4). Drillr has 2 published research articles covering TMO.
Thermo Fisher Scientific Inc. (TMO) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 9 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
TMO earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Apr 23, 2026 | $5.25 | $5.44 | +3.6% | $11.0B | +1.3% |
| Jan 29, 2026 | $6.45 | $6.57 | +1.9% | $12.2B | +2.2% |
| Oct 22, 2025 | $5.50 | $5.79 | +5.3% | $11.1B | +1.9% |
| Jul 23, 2025 | $5.23 | $5.36 | +2.5% | $10.9B | +1.6% |
| Apr 23, 2025 | $5.10 | $5.15 | +1.0% | $10.4B | +1.3% |
| Jan 30, 2025 | $5.94 | $6.10 | +2.7% | $11.4B | +1.0% |
| Oct 23, 2024 | $5.25 | $5.28 | +0.6% | $10.6B | -0.3% |
| Jul 24, 2024 | $5.12 | $5.37 | +4.9% | $10.5B | +0.3% |
| Jan 31, 2024 | $5.64 | $5.67 | +0.5% | $10.9B | +1.5% |
| Oct 25, 2023 | $5.61 | $5.69 | +1.4% | $10.6B | -0.7% |
| Jul 26, 2023 | $5.43 | $5.15 | -5.2% | $10.7B | -2.7% |
| Feb 1, 2023 | $5.19 | $5.40 | +4.0% | $11.4B | +9.8% |
TMO insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| May 22, 2026 | Jacks Tylerdirector | Grant | 499 | — |
| May 22, 2026 | JOHNSON JENNIFER Mdirector | Grant | 499 | — |
| May 22, 2026 | Keith R. Alexandradirector | Grant | 499 | — |
| May 22, 2026 | HARRIS C MARTINdirector | Grant | 499 | — |
| May 22, 2026 | Lynch Karen Sdirector | Grant | 499 | — |
| May 22, 2026 | Spar Debora Ldirector | Grant | 499 | — |
| May 22, 2026 | WEISLER DION Jdirector | Grant | 499 | — |
| May 22, 2026 | Chai Nelsondirector | Grant | 499 | — |
| May 22, 2026 | WEISLER DION Jdirector | Tax | 80 | $451.79 |
| May 22, 2026 | SPERLING SCOTT Mdirector | Grant | 499 | — |
| May 22, 2026 | CHANDY RUBY Rdirector | Grant | 499 | — |
| Apr 29, 2026 | Pettiti Gianlucaofficer: President & COO | Sell | 400 | $462.66 |
| Mar 31, 2026 | Lynch Karen Sdirector | Grant | 66 | — |
| Mar 31, 2026 | JOHNSON JENNIFER Mdirector | Grant | 66 | — |
| Mar 31, 2026 | WEISLER DION Jdirector | Grant | 79 | — |
Source: TMO SEC Form 4 filings, latest May 22, 2026. For informational purposes only — not investment advice.
See the full TMO insider & 13F page →TMO research & analysis
Trump 100% Pharma Tariffs: PFE and MRK Face $200M Hit While LLY Gains 25%
Trump's proposed 100% pharma tariffs and China's biotech surge, per April 11 CNBC, threaten Europe's manufacturing edge, hiking costs for PFE (-2.8% 1M) and MRK (-5.1% 1M) while LLY's US focus drives 25% 2026 growth. Supply chain filings flag $100-200M hits; investors should fade exposed names, buy domestic leaders. Next catalysts: Earnings tariff disclosures and China trade flows.
PFEMRKLLYPharma Tariffs: LLY, TMO, CVS Supply Chain Exposure Ranked by Risk
Trump's April 2 pharma tariff announcement highlights supply chain risks for LLY, TMO, and CVS, with SEC filings exposing China reliance. Stocks dipped mildly, but domestic manufacturing offers protection amid margin pressures.
PFEMRKLLY
Thermo Fisher Scientific Inc. company profile
Overview
Thermo Fisher Scientific Inc. (NYSE:TMO) is a leading American multinational biotechnology company founded in 1956 and headquartered in Waltham, Massachusetts. The company went public in 1980 and has grown through strategic acquisitions and organic expansion to become one of the world's largest providers of scientific instrumentation, reagents, consumables, software, and services. Thermo Fisher serves the life sciences, healthcare, industrial, and applied markets globally, with operations spanning North America, Europe, Asia-Pacific, and other international markets. The company has established itself as a critical partner to pharmaceutical companies, biotechnology firms, academic institutions, government agencies, and clinical laboratories worldwide.
Business
Thermo Fisher Scientific operates in the life sciences and healthcare technology sector, providing essential tools and services that enable scientific research, drug development, clinical diagnostics, and quality control across multiple industries. The company's offerings span the entire scientific workflow from basic research to clinical application. The company operates through four main business segments: Life Sciences Solutions represents the largest segment, generating approximately 40% of total revenue. This division provides reagents, instruments, and consumables essential for biological and medical research, drug discovery, vaccine development, and disease diagnosis. Key products include cell culture media, molecular biology reagents, protein analysis tools, and genetic sequencing technologies. The segment serves pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets with solutions for biosciences, genetic sciences, and bioproduction applications. Analytical Instruments accounts for roughly 25% of revenue and offers sophisticated scientific instruments, consumables, software, and services. This segment provides mass spectrometers, chromatography systems, electron microscopes, and other analytical equipment used by pharmaceutical, biotechnology, academic, government, environmental, and industrial laboratories. These instruments are critical for materials characterization, environmental monitoring, food safety testing, and pharmaceutical quality control. Specialty Diagnostics generates approximately 15% of revenue, focusing on clinical diagnostic solutions. The division develops and manufactures immunodiagnostic reagent kits, calibrators, controls, and instruments for clinical laboratories. Key applications include allergy testing, autoimmune disease monitoring, transplant compatibility testing, and infectious disease diagnosis. Products are sold as complete blood test systems supporting clinical diagnosis across various medical specialties. Laboratory Products and Biopharma Services comprises about 20% of revenue and includes two main components: laboratory products distribution and pharmaceutical services. The laboratory products channel distributes scientific equipment and supplies to research institutions, while the biopharma services component provides contract development and manufacturing services, clinical research services, and regulatory support to pharmaceutical and biotechnology companies throughout the drug development lifecycle.
Revenue model
Thermo Fisher Scientific generates revenue through multiple complementary business models that create recurring and diversified income streams. Product Sales constitute the primary revenue source, with the company selling scientific instruments, reagents, consumables, and laboratory supplies. Instruments typically represent higher-value, lower-frequency purchases, while reagents and consumables provide recurring revenue as customers continuously replenish these materials for ongoing research and testing activities. The consumables business model is particularly attractive as it generates predictable, repeat purchases with higher margins. Service Revenues come from maintenance contracts, technical support, and professional services associated with the company's instruments and systems. These services provide steady, recurring income and help maintain strong customer relationships while ensuring optimal instrument performance. Contract Services through the biopharma services segment generate fees for drug development, manufacturing, and clinical research services. This includes contract research organization (CRO) services, contract development and manufacturing organization (CDMO) services, and regulatory consulting. Revenue is typically project-based or capacity-based, with some long-term contracts providing visibility. The company's customers include pharmaceutical and biotechnology companies, academic and research institutions, government agencies, clinical laboratories, and industrial companies. Large pharmaceutical companies represent significant customers for both products and services, while academic institutions and smaller biotech firms provide broad-based demand. Several factors influence Thermo Fisher's profitability and margins. Positive factors include the company's scale advantages in manufacturing and procurement, strong market positions in specialized niches, recurring consumables revenue, and the essential nature of its products for customers' operations. The company benefits from scientific innovation trends, aging demographics driving healthcare demand, and increasing regulatory requirements for testing and quality control. Challenging factors include macroeconomic conditions affecting customer spending, particularly in biotechnology funding cycles, competitive pressure in certain product categories, foreign exchange fluctuations, and geopolitical tensions affecting international operations. Raw material costs, supply chain disruptions, and regulatory changes can also impact margins. The company has demonstrated resilience through economic cycles by maintaining operational discipline and leveraging its diversified portfolio.
Competitive moat
Thermo Fisher Scientific possesses a strong and multi-faceted competitive moat built on several reinforcing advantages that create significant barriers to entry and customer switching costs. The company's scale and scope advantages are substantial, with its size enabling superior R&D investment, global manufacturing efficiency, and comprehensive product portfolios that competitors struggle to match. This scale allows Thermo Fisher to serve customers' complete workflows, from basic research through clinical application, creating convenience and integration benefits that smaller competitors cannot replicate. High switching costs represent another key moat element. Customers invest significant time and resources training personnel on specific instruments and workflows, validating methods for regulatory compliance, and integrating systems into their operations. The cost and disruption of switching to alternative suppliers often outweigh potential savings, particularly in regulated environments where validation requirements are stringent. The mission-critical nature of many products creates customer dependency and pricing power. Scientific research, drug development, and clinical diagnostics cannot proceed without reliable instrumentation and reagents, making customers relatively price-insensitive for essential products. Quality and reliability often take precedence over cost considerations. Network effects emerge through the company's installed base of instruments, which drives recurring consumables sales and creates data network advantages. The company's broad customer relationships also provide valuable market intelligence for product development and strategic planning. However, the moat faces several potential challenges. Technological disruption could emerge from new analytical methods, automation technologies, or digital solutions that bypass traditional approaches. Competition from specialized players in specific niches could erode market share, while customer consolidation in pharmaceuticals increases buyer power. Regulatory changes or shifts in research funding could alter demand patterns. Additionally, geopolitical tensions and trade restrictions could limit the company's global reach advantages. Despite these challenges, Thermo Fisher's moat remains robust due to the essential nature of its products, high customer switching costs, and the company's ability to invest in innovation and strategic acquisitions to maintain technological leadership.
Risks & safety
Overall Assessment: Thermo Fisher demonstrates strong financial stability with solid cash generation, manageable debt levels, and reasonable valuation metrics, though recent quarters show some margin pressure. Liquidity and Solvency: - Cash and short-term investments: $4.1 billion (Q1 2025) - Current ratio: 1.77, indicating solid short-term liquidity - Debt-to-equity ratio: 0.69, representing moderate leverage - Strong free cash flow generation: $361 million (Q1 2025), $7.3 billion (FY 2024) - Operating cash flow remains robust at $8.7 billion annually Valuation Metrics: - P/E ratio: 31.4x, elevated but reasonable for a quality healthcare technology company - EV/EBITDA: 31.9x (Q1 2025), indicating premium valuation - Price-to-book ratio: 3.83x, reflecting strong intangible assets and market position - Return on equity: 12.8% (FY 2024), demonstrating efficient capital utilization Other Considerations: - Consistent dividend payments with recent 10% increase - Active share repurchase program ($1 billion in Q1 2025) - Recent major acquisition (Solventum's purification business for $4.1 billion) will increase leverage temporarily - Exposure to macroeconomic headwinds including tariffs ($400 million expected impact) and biotech funding cycles
Recent development
Over the past few years, Thermo Fisher has pursued several key strategic initiatives focused on innovation, partnerships, and strategic acquisitions to strengthen its market position and drive growth. High-Impact Innovation Strategy: The company has consistently launched breakthrough products across its portfolio, including the Orbitrap Astral Mass Spectrometer, which has gained significant market traction, the Thermo Scientific Stellar Mass Spectrometer, and the recently introduced Vulcan automated lab for semiconductor manufacturing. The company has also expanded its proteomics capabilities with the launch of Olink Reveal kits for precision medicine applications and introduced the Transcend ultra-high-performance liquid chromatography platform. Strategic Acquisitions: Thermo Fisher completed several significant acquisitions to expand capabilities and market reach. The acquisition of Olink in 2024 strengthened the company's position in proteomics and precision medicine. The company also acquired The Binding Site to enhance its specialty diagnostics portfolio. Most recently, Thermo Fisher announced the acquisition of Solventum's purification and filtration business for $4.1 billion, which will expand its bioproduction capabilities. Partnership Strategy: The company has formed strategic partnerships to accelerate innovation and market access, including collaborations with the National Cancer Institute for precision medicine trials, partnerships with the Chan Zuckerberg Institute for Advanced Biological Imaging, and alliances with the University of Arkansas for research initiatives. These partnerships provide access to cutting-edge research and help validate new technologies. Manufacturing and Service Expansion: Thermo Fisher has significantly expanded its manufacturing footprint, particularly in pharmaceutical services, with new facilities in Cincinnati and Bend, and expanded global laboratory services with new bioanalytical labs in Sweden. The company has also introduced new service offerings like the Accelerator Drug Development solution to support pharmaceutical customers. Digital Transformation: The company has invested in digital solutions and automation, including the Unity Lab Services platform for laboratory management and various software solutions that integrate with its hardware offerings to provide comprehensive workflow solutions.
TMO company profile · for informational purposes only — not investment advice.
Track TMO with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free